IFx-Hu2.0
CM 2017-01
Phase 1 mab completed
Quick answer
IFx-Hu2.0 for Cutaneous Melanoma, Stage III is a Phase 1 program (mab) at TuHURA Biosciences, Inc./NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TuHURA Biosciences, Inc./NV
- Indication
- Cutaneous Melanoma, Stage III
- Phase
- Phase 1
- Modality
- mab
- Status
- completed